Akseli Hemminki

机构：University of Helsinki, Helsinki University Hospital · ORCID：0000-0001-7103-8530

发表论文 649 篇 · 总被引 28962 次 · h-index 78

代表论文

• The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial (2025 · Nature Communications · 被引 34)
• Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors (2024 · Journal of Experimental & Clinical Cancer Research · 被引 24)
• Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma (2025 · Cell Reports Medicine · 被引 19)
• Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial (2025 · Journal for ImmunoTherapy of Cancer · 被引 9)
• Age-specific familial risks in cancer as clues to germline genetic and environmental causes: focus on colorectal, endometrial, prostate, kidney, breast and lung cancers (2025 · Hereditary Cancer in Clinical Practice · 被引 7)
• Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models (2025 · Cancer Immunology Immunotherapy · 被引 6)